Abstract: Described are methods of inhibiting one or more pharmaceutical agent from binding to a plasma protein so it binds to its target. Specifically, a plasma protein binding agent is administered prior to, concurrently with, or after the administration of one or more pharmaceutical agents that binds to a plasma protein in vivo. The methods of the present invention allow pharmaceutical agents that bind to plasma binding proteins to treat disease cells in vivo.

Abstract: Integrating a direct current (DC) voltage motion sensing alarm with an alternating current (AC) voltage light source is presented herein. A wall switch box can comprise a voltage conversion component that generates a DC voltage from an AC voltage that is higher in magnitude than the DC voltage, a motion sensing component detects a motion of an object using the DC voltage, and a security component that generates, based on the motion using the DC voltage, an alarm signal that has been encoded according to an encryption strength of a communication protocol corresponding to a transmission of the alarm signal from the wall switch box. In one aspect, a communication expansion component can wirelessly transmit, using the DC voltage based on control information specifying the communication protocol, the alarm signal according to the encryption strength. In another aspect, the encryption strength can correspond to at least 2128 combinations.

Abstract: Integrating a direct current (DC) voltage motion sensing alarm with an alternating current (AC) voltage light source is presented herein. An apparatus can include a voltage conversion component that generates, within a wall switch box, a DC voltage from an AC voltage that is higher in magnitude than the DC voltage, and a motion sensing component that detects, from the wall switch box using the DC voltage, a motion of an object. The motion sensing component can detect the motion using an infrared and/or ultrasonic based DC sensor. The apparatus can further include a security component that generates, from the wall switch box using the DC voltage, an alarm signal and/or wireless alarm signal based on the motion, and a power component that switches, from the wall switch box using the DC voltage based on the motion, the AC voltage from a first contact to a second contact.

Abstract: Integrating a direct current (DC) voltage motion sensing alarm with an alternating current (AC) voltage light source is presented herein. A wall switch box can comprise a voltage conversion component that generates a DC voltage from an AC voltage that is higher in magnitude than the DC voltage, a motion sensing component detects a motion of an object using the DC voltage, and a security component that generates, based on the motion using the DC voltage, an alarm signal that has been encoded according to an encryption strength of a communication protocol corresponding to a transmission of the alarm signal from the wall switch box. In one aspect, a communication expansion component can wirelessly transmit, using the DC voltage based on control information specifying the communication protocol, the alarm signal according to the encryption strength. In another aspect, the encryption strength can correspond to at least 2128 combinations.

Abstract: Integrating a direct current (DC) voltage motion sensing alarm with an alternating current (AC) voltage light source is presented herein. An apparatus can include a voltage conversion component that generates, within a wall switch box, a DC voltage from an AC voltage that is higher in magnitude than the DC voltage, and a motion sensing component that detects, from the wall switch box using the DC voltage, a motion of an object. The motion sensing component can detect the motion using an infrared and/or ultrasonic based DC sensor. The apparatus can further include a security component that generates, from the wall switch box using the DC voltage, an alarm signal and/or wireless alarm signal based on the motion, and a power component that switches, from the wall switch box using the DC voltage based on the motion, the AC voltage from a first contact to a second contact.

Abstract: Integrating a direct current (DC) voltage motion sensing alarm with an alternating current (AC) voltage light source is presented herein. An apparatus can include a voltage conversion component that generates, within a wall switch box, a DC voltage from an AC voltage that is higher in magnitude than the DC voltage, and a motion sensing component that detects, from the wall switch box using the DC voltage, a motion of an object. The motion sensing component can detect the motion using an infrared and/or ultrasonic based DC sensor. The apparatus can further include a security component that generates, from the wall switch box using the DC voltage, an alarm signal and/or wireless alarm signal based on the motion, and a power component that switches, from the wall switch box using the DC voltage based on the motion, the AC voltage from a first contact to a second contact.

Abstract: Integrating a direct current (DC) voltage motion sensing alarm with an alternating current (AC) voltage light source is presented herein. An apparatus can include a voltage conversion component that generates, within a wall switch box, a DC voltage from an AC voltage that is higher in magnitude than the DC voltage, and a motion sensing component that detects, from the wall switch box using the DC voltage, a motion of an object. The motion sensing component can detect the motion using an infrared and/or ultrasonic based DC sensor. The apparatus can further include a security component that generates, from the wall switch box using the DC voltage, an alarm signal and/or wireless alarm signal based on the motion, and a power component that switches, from the wall switch box using the DC voltage based on the motion, the AC voltage from a first contact to a second contact.

Abstract: Disclosed herein are methods and compositions for treating leukemia and preventing leukemia relapse related to the administration of agents that inhibit the binding of FLT3 ligand to FLT3.

Abstract: New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.

Abstract: A novel protein tyrosine kinase, JAK3, and a polynucleotide sequence encoding JAK3 polypeptide are disclosed herein. JAK3 is a new member of the JAK family of protein tyrosine kinases which are important in regulation of cellular proliferation and differentiation. Also disclosed are therapeutic methods utilizing JAK3 polypeptide and polynucleotide sequences.

Abstract: A novel protein tyrosine kinase, JAK3, and a polynucleotide sequence encoding JAK3 polypeptide are disclosed herein. JAK3 is a new member of the JAK family of protein tyrosine kinases which are important in regulation of cellular proliferation and differentiation. Also disclosed are therapeutic methods utilizing JAK3 polypeptide and polynucleotide sequences.

Abstract: Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the STK-1 gene. These "antisense" oligonucleotides are hybridizable to the STK-1 mRNA transcript. Such oligonucleotides are useful in treating neoplastic diseases characterized by activation of STK-1 gene expression. The oligonucleotides are also useful as bone marrow purging agents in the treatment of leukemia and metastasized neoplasms.